Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Nat Rev Endocrinol ; 13(11): 644-660, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28707679

ABSTRACT

Anaplastic thyroid carcinoma (ATC) is a rare malignancy, accounting for 1-2% of all thyroid cancers. Although rare, ATC accounts for the majority of deaths from thyroid carcinoma. ATC often originates in a pre-existing thyroid cancer lesion, as suggested by the simultaneous presence of areas of differentiated or poorly differentiated thyroid carcinoma. ATC is characterized by the accumulation of several oncogenic alterations, and studies have shown that an increased number of oncogenic alterations equates to an increased level of dedifferentiation and aggressiveness. The clinical management of ATC requires a multidisciplinary approach; according to recent American Thyroid Association guidelines, surgery, radiotherapy and/or chemotherapy should be considered. In addition to conventional therapies, novel molecular targeted therapies are the most promising emerging treatment modalities. These drugs are often multiple receptor tyrosine kinase inhibitors, several of which have been tested in clinical trials with encouraging results so far. Accordingly, clinical trials are ongoing to evaluate the safety, efficacy and effectiveness of these new agents. This Review describes the updated clinical and pathological features of ATC and provides insight into the molecular biology of this disease. The most recent literature regarding conventional, newly available and future therapies for ATC is also discussed.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Radiotherapy , Thyroid Carcinoma, Anaplastic/therapy , Thyroid Neoplasms/therapy , Thyroidectomy , Age Factors , Deglutition Disorders/etiology , Dyspnea/etiology , GTP Phosphohydrolases/genetics , Hoarseness/etiology , Humans , Membrane Proteins/genetics , Neck Pain/etiology , Neoplasm Staging , Proto-Oncogene Proteins B-raf/genetics , Proto-Oncogene Proteins p21(ras)/genetics , Radiation Exposure/statistics & numerical data , Respiratory Sounds/etiology , Risk Factors , Stilbenes/therapeutic use , Telomerase/genetics , Thiazolidinediones/therapeutic use , Thyroid Carcinoma, Anaplastic/complications , Thyroid Carcinoma, Anaplastic/genetics , Thyroid Carcinoma, Anaplastic/pathology , Thyroid Neoplasms/complications , Thyroid Neoplasms/genetics , Thyroid Neoplasms/pathology
2.
Onco Targets Ther ; 9: 6467-6477, 2016.
Article in English | MEDLINE | ID: mdl-27799794

ABSTRACT

Lenvatinib is a small oral molecule able to inhibit three of the extracellular and intracellular molecules involved in the modulation of angiogenesis and lymphangiogenesis: vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-4, and platelet-derived growth factor receptor alpha. Since it is also able to inhibit the REarranged during Transfection oncogene and the protooncogene c-KIT, this drug can also be used to control tumor cell proliferation. The maximum tolerated dose, as demonstrated in Phase I studies, is 25 mg daily. The drug is rapidly absorbed with maximum concentrations achieved within 3 and 5 hours after administration in fasting and nonfasting treated patients, respectively. The most common adverse events, reported in Phase I study and confirmed in the subsequent Phase II and III studies, are hypertension, proteinuria, and gastrointestinal symptoms such as nausea, diarrhea, and stomatitis. In Phase I studies, efficacy of lenvatinib in solid tumors was demonstrated, and these encouraging results have led to the development of a Phase II study using lenvatinib in advance radioiodine-refractory differentiated thyroid cancer (DTCs) patients. Since an overall response rate of 50% was reported, this study also confirmed the efficacy of lenvatinib in DTCs patients with an acceptable toxicity profile. Recently, a Phase III study in patients with DTCs (SELECT study) demonstrated the lenvatinib efficacy in prolonging progression-free survival with respect to the placebo (18.3 vs 3.6 months; P<0.001). Although there was no statistically significant difference in the overall survival of the entire group, this result was observed when the analysis was restricted to both the follicular histotype and the group of senior patients (>65 years). The study confirmed that the most common side effects of this drug are hypertension, diarrhea, decreased appetite, weight loss, nausea, and proteinuria. In this review, we report the results of the main studies on lenvatinib efficacy in patients with advanced and progressive thyroid cancer, mainly in DTCs but also in medullary and anaplastic thyroid cancer. We also compared the efficacy of lenvatinib with that of other tyrosine kinase inhibitors, mainly sorafenib, already tested in the same type of patient population.

3.
Endocr Relat Cancer ; 23(4): R185-205, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27207700

ABSTRACT

Thyroid cancer is rare, but it is the most frequent endocrine malignancy. Its prognosis is generally favorable, especially in cases of well-differentiated thyroid cancers (DTCs), such as papillary and follicular cancers, which have survival rates of approximately 95% at 40 years. However, 15-20% of cases became radioiodine refractory (RAI-R), and until now, no other treatments have been effective. The same problems are found in cases of poorly differentiated (PDTC) and anaplastic (ATC) thyroid cancers and in at least 30% of medullary thyroid cancer (MTC) cases, which are very aggressive and not sensitive to radioiodine. Tyrosine kinase inhibitors (TKIs) represent a new approach to the treatment of advanced cases of RAI-R DTC, MTC, PDTC, and, possibly, ATC. In the past 10 years, several TKIs have been tested for the treatment of advanced, progressive, and RAI-R thyroid tumors, and some of them have been recently approved for use in clinical practice: sorafenib and lenvatinib for DTC and PDTC and vandetanib and cabozantinib for MTC. The objective of this review is to present the current status of the treatment of advanced thyroid cancer with the use of innovative targeted therapies by describing both the benefits and the limits of their use based on the experiences reported so far. A comprehensive analysis and description of the molecular basis of these therapies, as well as new therapeutic perspectives, are reported. Some practical suggestions are given for both the choice of patients to be treated and their management, with particular regard to the potential side effects.


Subject(s)
Thyroid Neoplasms/drug therapy , Animals , Humans , Molecular Targeted Therapy , Thyroid Neoplasms/genetics
4.
Laryngoscope ; 125(10): 2417-24, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25891354

ABSTRACT

OBJECTIVE: Recent, more selective use of radioactive iodine (RAI) has led to reevaluation of the clinical importance of achieving complete total thyroidectomy with minimal residual normal thyroid tissue. We utilize the improved localization by post-RAI remnant ablation, single photon emission computerized tomography-computed tomography (SPECT-CT) to define specific anatomic sites of residual RAI-uptake foci after total thyroidectomy for differentiated thyroid cancer (DTC) and to provide a novel classification system relating uptake to thyroid anatomy and preservation of adjacent neural structures. STUDY DESIGN: Retrospective. METHOD: Radioactive iodine-uptake foci in thyroid bed were localized by SPECT/CT imaging at the time of RAI remnant ablation in 141 DTC patients undergoing total thyroidectomy. RESULTS: Minimal residual RAI uptake (median 0.32% at 24 hours) in the thyroid bed was detected by diagnostic planar whole body scans in 93% and by posttherapy SPECT/CT imaging in 99% of subjects. Discrete RAI uptake foci were identified on the SPECT/CT imaging at Berry's ligament (87%), at superior thyroid poles (79%), in paratracheal-lobar regions (67%), in isthmus-region (54%), and in pyramidal lobe (46%). Despite the residual foci, the nonstimulated thyroglobulin (Tg) prior to remnant ablation (with a median thyroid-stimulating hormone of 0.36 m IU/L) was < 0.6 ng/mL in 53% and < 1 ng/mL in 73% of cases. CONCLUSION: After extracapsular total thyroidectomy, highly sensitive detection tools identify microscopic residual RAI avid foci in thyroid bed in the majority of patients. These foci can be classified as 1) neural-related and 2) capsule-related. These common residual foci have no relationship to postoperative Tg, suggesting that attempts at radical removal of thyroid tissue in these locations may not be warranted. LEVEL OF EVIDENCE: 4.


Subject(s)
Thyroid Gland/diagnostic imaging , Thyroid Neoplasms/surgery , Thyroidectomy , Ablation Techniques , Adult , Female , Humans , Iodine Radioisotopes/therapeutic use , Male , Middle Aged , Postoperative Period , Thyroid Gland/pathology , Thyroid Neoplasms/pathology , Thyroid Neoplasms/radiotherapy , Tomography, Emission-Computed, Single-Photon , Tomography, X-Ray Computed
5.
Clin Endocrinol (Oxf) ; 82(6): 892-9, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25440022

ABSTRACT

OBJECTIVE: Medullary thyroid carcinoma (MTC) is a rare disease that can be inherited or sporadic; its pathogenesis is related to activating mutations in the RET gene. DESIGN: This study describes our 20-year experience regarding RET genetic screening in MTC. PATIENTS AND METHODS: We performed RET genetic screening in 1556 subjects, 1007 with an apparently sporadic MTC, 95 with a familial form and 454 relatives of RET-positive patients with MTC. RESULTS: A germline RET mutation was found in 68 of 1007 (6·7%) patients with sporadic MTC, while 939 patients with MTC were negative for germline RET mutations. We then identified a total of 137 gene carriers (GC). These subjects initiated a clinical evaluation for the diagnosis of MEN 2. A total of 139 MEN 2 families have been followed: 94 FMTC, 33 MEN 2A and 12 MEN 2B. Thirty-three different germline RET mutations were identified. Codon 804 was the most frequently altered codon particularly in FMTC (32/94, 34%), while codon 634 was the most frequently altered codon in MEN 2A (31/33, 94%); MEN 2B cases were exclusively associated with an M918T mutation at exon 16. CONCLUSIONS: Our 20-year study demonstrated that RET genetic screening is highly specific and sensitive, and it allows the reclassification as hereditary of apparently sporadic cases and the identification of GC who require an adequate follow-up. We confirmed that FMTC is the most prevalent MEN 2 syndrome and that it is strongly correlated with noncysteine RET mutations. According to these findings, a new paradigm of follow-up of hereditary MTC cases might be considered in the next future.


Subject(s)
Carcinoma, Medullary/congenital , Multiple Endocrine Neoplasia Type 2a/genetics , Multiple Endocrine Neoplasia Type 2b , Proto-Oncogene Proteins c-ret/genetics , Thyroid Neoplasms/genetics , Adult , Carcinoma, Medullary/diagnosis , Carcinoma, Medullary/genetics , Early Detection of Cancer , Female , Genetic Testing , Germ-Line Mutation , Heterozygote , Humans , Italy , Male , Middle Aged , Multiple Endocrine Neoplasia Type 2a/diagnosis , Multiple Endocrine Neoplasia Type 2b/diagnosis , Multiple Endocrine Neoplasia Type 2b/genetics , Sensitivity and Specificity , Thyroid Gland/pathology , Thyroid Neoplasms/diagnosis
6.
Endocrinol Metab Clin North Am ; 43(2): 331-44, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24891165

ABSTRACT

Serum thyroglobulin (sTg) is the marker for monitoring persistence/recurrence of differentiated thyroid cancer, in patients without sTg antibodies. Patients with undetectable basal sTg or peak sTg <2 ng/mL are cured with low risk to recur. Newly detectable level of sTg indicates the recurrence. The significance of increasing sTg in patients treated with emithyroidectomy or total-thyroidectomy but not ablated with radioiodine is undefined. A doubling time <1 year may be a poor prognostic factor, but this is more relevant in cases with high levels of sTg. Because of its sensitivity, neck ultrasound should be performed at any visit, especially when an increased sTg is seen.


Subject(s)
Neoplasm Recurrence, Local/diagnosis , Thyroglobulin/blood , Thyroid Neoplasms/diagnosis , Diagnostic Imaging , Humans , Neoplasm Recurrence, Local/blood , Prognosis , Thyroid Neoplasms/blood
7.
Thyroid ; 24(2): 245-53, 2014 Feb.
Article in English | MEDLINE | ID: mdl-23745671

ABSTRACT

BACKGROUND: There continues to be controversy regarding which clinicopathological features confer a higher risk of adverse outcome in papillary microcarcinomas (PMC). The aim of this study was to assess the prognostic value of a meticulous histologic examination in PMC. METHOD: All papillary thyroid carcinoma <1 cm in size without associated larger thyroid carcinomas, identified between 1977 and 2002, were categorized as PMC and subjected to a meticulous histopathologic examination by 2 thyroid pathologists. RESULTS: 148 PMC patients fulfilled the inclusion criteria. Within PMC, young age, male sex, tumor multicentricity, extrathyroidal extension, and infiltrative and larger tumor (≥0.5 cm) correlated with the presence of >1 cm metastatic node (MN) or >3 MN at presentation (p<0.05). With a median follow-up of 9.9 years, only 1 (0.7%) of 134 PMC patients died of thyroid carcinomas and 3 (2.2%) had recurrences in the neck. The patient who died had harbored a poorly differentiated carcinoma in his MN. The presence of MN and especially a large MN (>1 cm) correlated with worse recurrence-free survival (p=0.005 and p<0.0001, respectively). Except for one, all individuals with clinically adverse outcomes had >1 cm MN. Patients whose MNs were predominantly composed of poorly differentiated carcinoma or tall cell variant papillary thyroid carcinoma had a significant shorter recurrence-free survival (p<0.0001). Only 1 of 80 radioactive iodine-naïve PMC patients with absent or small MN (≤1 cm) had recurrence with a median follow-up of 9.2 years. CONCLUSIONS: (i) The size and histotype of the MN are predictors of outcome in PMC and should be recorded. (ii) The very rare PMC patients who suffer recurrence or even die of disease have usually aggressive histopathologic features at presentation. (iii) PMC patients with nodal disease that is small or absent at presentation are at a very low risk of recurrence and may be spared radioactive iodine therapy.


Subject(s)
Carcinoma, Papillary/pathology , Carcinoma/pathology , Thyroid Neoplasms/pathology , Adolescent , Adult , Aged , Carcinoma/epidemiology , Carcinoma/therapy , Carcinoma, Papillary/epidemiology , Carcinoma, Papillary/therapy , Child , Disease-Free Survival , Female , Humans , Incidence , Lymphatic Metastasis/pathology , Male , Middle Aged , Neoplasm Recurrence, Local/pathology , Prognosis , Retrospective Studies , Thyroid Cancer, Papillary , Thyroid Neoplasms/epidemiology , Thyroid Neoplasms/therapy , Thyroidectomy
8.
J Clin Endocrinol Metab ; 98(7): 2693-700, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23626005

ABSTRACT

BACKGROUND: No long-term follow-up data are available for differentiated thyroid carcinoma (DTC) patients prepared with either exogenous or endogenous TSH and treated with low-activity (1.1 GBq [30 mCi]) radioiodine (¹³¹I). AIM: The aim of this study was to evaluate the 10-year follow-up of DTC patients who underwent remnant ablation with 1.1 GBq ¹³¹I after l-T4 withdrawal, recombinant human TSH (rhTSH) administration, or both. PATIENTS: A total of 159 DTC patients treated with total thyroidectomy and 1.1 GBq (30 mCi) of ¹³¹I for remnant ablation and stimulated with rhTSH and/or endogenous TSH were separated into ablated (n = 115) and not ablated (n = 44) patients and prospectively followed-up for at least 10 years. In addition, we evaluated several features that could correlate with the final status of patients. RESULTS: During the follow-up, 4 of 115 (3.5%) ablated patients showed a recurrence and 1 was successfully cured. Among not ablated patients, 16 of 44 (36.4%) had a persistent disease. At the end of the 10-year follow-up, 140 of 159 (88.1%) patients were disease-free, whereas 19 of 159 (11.9%) remained affected. No correlation was found with the type of TSH stimulation, and no other clinical and pathological features showed any correlation with the final status. However, low levels of stimulated serum thyroglobulin (<5.4 ng/mL) at first control after remnant ablation identified a subgroup of not ablated patients who became spontaneously cured. CONCLUSIONS: Long-term outcomes are similar in DTC patients treated with 1.1 GBq (30 mCi) ¹³¹I and prepared either with rhTSH or endogenous TSH. It is of interest that serum thyroglobulin at first control after ablation can have a prognostic role.


Subject(s)
Iodine Radioisotopes/therapeutic use , Premedication , Radiopharmaceuticals/therapeutic use , Thyroid Gland/radiation effects , Thyroid Neoplasms/radiotherapy , Thyrotropin/therapeutic use , Thyroxine/administration & dosage , Adult , Combined Modality Therapy , Disease-Free Survival , Female , Follow-Up Studies , Humans , Iodine Radioisotopes/administration & dosage , Male , Middle Aged , Neoplasm Recurrence, Local , Prognosis , Prospective Studies , Radiopharmaceuticals/administration & dosage , Recombinant Proteins/therapeutic use , Remission Induction , Thyroglobulin/blood , Thyroid Gland/drug effects , Thyroid Gland/metabolism , Thyroid Gland/surgery , Thyroid Neoplasms/diagnosis , Thyroid Neoplasms/drug therapy , Thyroid Neoplasms/surgery , Thyroidectomy , Thyrotropin/blood , Thyrotropin/metabolism , Thyroxine/therapeutic use
9.
J Clin Endocrinol Metab ; 97(12): 4390-8, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23066120

ABSTRACT

BACKGROUND: The BRAF(V600E) mutation, the most frequent genetic alteration in papillary thyroid carcinoma (PTC), was demonstrated to be a poor prognostic factor. The aim of this study was to evaluate its prognostic significance in a large cohort of low-risk intrathyroid PTC. METHODS: Among the 431 consecutive PTC patients, we selected 319 patients with an intrathyroid tumor and no metastases (T1-T2, N0, M0). The BRAF(V600E) mutation was analyzed by PCR-single-strand conformation polymorphism analysis and direct genomic sequencing. The correlation between the presence/absence of the mutation, the clinical-pathological features, and the outcome of the PTC patients was investigated. RESULTS: The BRAF(V600E) mutation was present in 106 of 319 PTC patients (33.2%). Its prevalence was also the same in subgroups identified according to the level of risk. The BRAF(V600E) mutation correlated with multifocality, aggressive variant, absence, or infiltration of the tumoral capsule. BRAF(V600E)-mutated PTC also required a higher number of radioiodine courses to obtain disease-free status. The BRAF(V600E) mutation was the only prognostic factor predicting the persistence of the disease in these patients after 5 yr of follow-up. CONCLUSIONS: The BRAF(V600E) mutation was demonstrated to be a poor prognostic factor for the persistence of the disease independent from other clinical-pathological features in low-risk intrathyroid PTC patients. It could be useful to search for the BRAF(V600E) mutation in the workup of low-risk PTC patients to distinguish those who require less or more aggressive treatments. In particular, the high negative predictive value of the BRAF(V600E) mutation could be useful to identify, among low-risk PTC patients, those who could avoid 131-I treatment.


Subject(s)
Carcinoma/diagnosis , Mutation, Missense , Proto-Oncogene Proteins B-raf/genetics , Thyroid Neoplasms/diagnosis , Adolescent , Adult , Aged , Aged, 80 and over , Amino Acid Substitution , Carcinoma/epidemiology , Carcinoma/genetics , Carcinoma, Papillary , Cohort Studies , Female , Genetic Predisposition to Disease , Glutamic Acid/genetics , Humans , Male , Middle Aged , Mutation, Missense/physiology , Prognosis , Proto-Oncogene Proteins B-raf/physiology , Risk Factors , Sample Size , Thyroid Cancer, Papillary , Thyroid Gland/pathology , Thyroid Neoplasms/epidemiology , Thyroid Neoplasms/genetics , Valine/genetics , Young Adult
10.
J Clin Endocrinol Metab ; 94(5): 1618-22, 2009 May.
Article in English | MEDLINE | ID: mdl-19223525

ABSTRACT

BACKGROUND: Minimally invasive video-assisted thyroidectomy (MIVAT) was introduced in the clinical practice to treat small benign thyroid nodules. This method has recently been demonstrated to produce the same completeness as a conventional thyroidectomy in patients with papillary thyroid cancer (PTC). The low number of treated cases and the limited follow-up of these patients represent the major limitations of these studies. OBJECTIVE: The aim of the study was to compare the outcome of two groups of PTC patients, one treated with MIVAT and the other with conventional thyroidectomy, after a median follow-up of 5 yr. STUDY GROUP: A total of 221 PTC patients were enrolled in this study according to the following criteria: 171 were treated with MIVAT (group A), and 50 were treated with conventional thyroidectomy (group B). RESULTS: The outcome and the cumulative (131)I activity administered to achieve curative status were compared. After a mean follow-up of 3.6 +/- 1.5 yr (range, 1-8 yr; median, 5 yr), no differences were found between group A and group B. A similar rate of permanent hypoparathyroidism and/or nerve cord palsy was found in both groups. CONCLUSION: We demonstrated that PTC patients operated on with MIVAT had a good outcome after 5 yr. This was similar to the outcome of patients treated with conventional thyroidectomy and the same degree of exposure to (131)I. These results, together with the evidence of a similar degree of completeness and rate of complications between the two surgical techniques, show that MIVAT is a valid option to treat low- and intermediate-risk PTC patients.


Subject(s)
Carcinoma, Papillary/surgery , Minimally Invasive Surgical Procedures/methods , Thyroid Neoplasms/surgery , Thyroidectomy/methods , Video-Assisted Surgery/methods , Adolescent , Adult , Aged , Carcinoma, Papillary/pathology , Carcinoma, Papillary/radiotherapy , Child , Female , Follow-Up Studies , Humans , Hypoparathyroidism/epidemiology , Hypoparathyroidism/etiology , Iodine Radioisotopes/therapeutic use , Male , Middle Aged , Minimally Invasive Surgical Procedures/adverse effects , Paralysis/epidemiology , Paralysis/etiology , Postoperative Complications/epidemiology , Risk , Thyroid Neoplasms/pathology , Thyroid Neoplasms/radiotherapy , Thyroidectomy/adverse effects , Treatment Outcome , Video-Assisted Surgery/adverse effects , Young Adult
11.
J Clin Endocrinol Metab ; 93(10): 3943-9, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18682506

ABSTRACT

BACKGROUND: The BRAF(V600E) mutation is the most frequent genetic alteration in papillary thyroid carcinoma (PTC). The role of BRAF(V600E) mutation as a poor prognostic factor has been controversially reported in series with short-term follow-ups. In this study we verified the prognostic value of the BRAF(V600E) mutation in PTC patients with a long-term follow-up. METHODS: We studied 102 PTC patients with a median follow-up of 15 yr. The BRAF(V600E) mutation was analyzed by PCR-single-strand conformational polymorphism and sequencing. The correlation between the presence/absence of the BRAF(V600E) mutation, clinicopathological features, and outcome of PTC patients were evaluated. RESULTS: The BRAF(V600E) mutation was found in 38 of 102 (37.3%) PTC patients, and was significantly more frequent in patients older than 60 yr (P = 0.02), in advanced stages (P = 0.03), and in cases with vascular invasion (P = 0.02). At univariate analysis the worst outcome for PTC patients was significantly correlated with clinicopathological features (i.e. age, tumor size, extrathyroid extension, lymph node and distant metastases, advanced stage, vascular endothelial growth factor expression, and vascular invasion) and the BRAF(V600E) mutation (P < 0.002). However, at multivariate analysis only the BRAF(V600E) mutation showed an independent correlation with the worst outcome (P = 0.03). Moreover, the survival curves of PTC patients showed a lower percentage of survivors in the BRAF(V600E)-mutated group (P = 0.015). CONCLUSIONS: In this study the BRAF(V600E) mutation correlated with the worst outcome for PTC patients, who were not only at a higher risk not to be cured but also for death. In particular, the BRAF(V600E) mutation was demonstrated to be a poor prognostic factor independent from other clinicopathological features.


Subject(s)
Carcinoma, Papillary/diagnosis , Point Mutation , Proto-Oncogene Proteins B-raf/genetics , Thyroid Neoplasms/diagnosis , Adolescent , Adult , Aged , Biomarkers, Tumor/genetics , Carcinoma, Papillary/genetics , Carcinoma, Papillary/mortality , Carcinoma, Papillary/pathology , Child , Disease Progression , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prognosis , Survival Analysis , Thyroid Neoplasms/genetics , Thyroid Neoplasms/mortality , Thyroid Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...